Journal of Biological Chemistry · 2005 · 238 citations · 25 references
Life SciencesCell BiologyMolecular BiologyCell SignalingMetabolic RegulationSignal TransductionNutrient SensingNutrient-sensing PathwaysProtein Kinase CascadesStress Signaling PathwaysCell Growth Control By NutrientsCell Growth RegulationCellular Stress SignalingMammalian Target Of Rapamycin SignalingMtor InhibitionMtor SignalingPi3k-akt-mtor SignalingSignaling Pathway Regulation
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays an essential role in cell growth control. mTOR stimulates cell growth by phosphorylating p70 ribosomal S6 kinase (S6K) and eukaryote initiation factor 4E-binding protein 1 (4EBP1). The mTOR pathway is regulated by a wide variety of cellular signals, including mitogenic growth factors, nutrients, cellular energy levels, and stress conditions. Recent studies have proposed several mechanisms to explain how mTOR is regulated by growth factors and cellular energy levels. However, little is known as to how mTOR is regulated by stress conditions. We observed that two stress-induced proteins, RTP801/Redd1 and RTP801L/Redd2, potently inhibit signaling through mTOR. Our data support that RTP801 and RTP801L work downstream of AKT and upstream of TSC2 to inhibit mTOR functions. These results add a new dimension to mTOR pathway regulation and provide a possible molecular mechanism of how cellular stress conditions may regulate mTOR function. The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays an essential role in cell growth control. mTOR stimulates cell growth by phosphorylating p70 ribosomal S6 kinase (S6K) and eukaryote initiation factor 4E-binding protein 1 (4EBP1). The mTOR pathway is regulated by a wide variety of cellular signals, including mitogenic growth factors, nutrients, cellular energy levels, and stress conditions. Recent studies have proposed several mechanisms to explain how mTOR is regulated by growth factors and cellular energy levels. However, little is known as to how mTOR is regulated by stress conditions. We observed that two stress-induced proteins, RTP801/Redd1 and RTP801L/Redd2, potently inhibit signaling through mTOR. Our data support that RTP801 and RTP801L work downstream of AKT and upstream of TSC2 to inhibit mTOR functions. These results add a new dimension to mTOR pathway regulation and provide a possible molecular mechanism of how cellular stress conditions may regulate mTOR function. A fundamental question in cell biology is how various extracellular cues can cause changes in translational output and hence the growth of the cell. The mammalian target of rapamycin (mTOR) 1The abbreviations used are: mTOR, mammalian target of rapamycin; S6K, S6 kinase; 4EBP1, eukaryote initiation factor 4E-binding protein 1; TSC, tuberous sclerosis complex; GAP, GTPase-activating protein; AMPK, AMP-activated protein kinase; HA, hemagglutinin; RNAi, RNA interference; siRNA, short interfering RNA. is a key regulator of translation that acts to stimulate protein synthesis by phosphorylating the ribosomal translation regulators p70 ribosomal S6 kinase (S6K) and eukaryote initiation factor 4E-binding protein 1 (4EBP1) (reviewed in Refs. 1Jacinto E. Hall M.N. Nat. Rev. Mol. Cell. Biol. 2003; 4: 117-126Crossref PubMed Scopus (513) Google Scholar, 2Fingar D.C. Blenis J. Oncogene. 2004; 23: 3151-3171Crossref PubMed Scopus (1064) Google Scholar, 3Harris T.E. Lawrence Jr., J.C. Science's STKE. 2003; 2003: re15PubMed Google Scholar, 4Hay N. Sonenberg N. Genes Dev. 2004; 18: 1926-1945Crossref PubMed Scopus (3461) Google Scholar). mTOR is known to receive inputs from multiple signaling pathways and responds by increasing or decreasing protein synthesis appropriately. A prominent example of this phenomenon is how mTOR is stimulated by growth factors and the availability of nutrients, while it is inhibited by conditions such as low ATP levels, the absence of nutrients, or cellular stressors such as DNA damage or hypoxia. Regulation of protein synthesis by mTOR is responsible for controlling cell size and proliferation, and it has recently been shown that mTOR may also regulate other cellular processes such as cytoskeletal organization, mRNA turnover, transcription, and autophagy (1Jacinto E. Hall M.N. Nat. Rev. Mol. Cell. Biol. 2003; 4: 117-126Crossref PubMed Scopus (513) Google Scholar). Dysregulation of the mTOR pathway in vivo is associated with several inherited human syndromes, including tuberous sclerosis complex (TSC), the PTEN hamartoma tumor syndromes, and Peutz-Jeghers Syndrome (5Manning B.D. J. Cell Biol. 2004; 167: 399-403Crossref PubMed Scopus (419) Google Scholar, 6Inoki K. Corradetti M.N. Guan K.L. Nat. Genet. 2004; 37: 19-34Crossref Scopus (842) Google Scholar). The tuberous sclerosis complex gene products, TSC1 and TSC2, are negative regulators of the mTOR signaling network (7Pan D. Dong J. Zhang Y. Gao X. Trends Cell Biol. 2004; 14: 78-85Abstract Full Text Full Text PDF PubMed Scopus (133) Google Scholar). TSC1 and TSC2 form a complex in the cell, and the integrity of the TSC1/2 complex is essential for either protein to function. Cells or tissues lacking TSC1 or TSC2 display high levels of mTOR activation as measured by the activation status of S6K and 4EBP1, indicating that the TSC1/2 complex negatively regulates mTOR function (8Tee A.R. Fingar D.C. Manning B.D. Kwiatkowski D.J. Cantley L.C. Blenis J. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 13571-13576Crossref PubMed Scopus (697) Google Scholar, 9Inoki K. Li Y. Zhu T. Wu J. Guan K.L. Nat. Cell Biol. 2002; 4: 648-657Crossref PubMed Scopus (2406) Google Scholar, 10Kwiatkowski D.J. Zhang H. Bandura J.L. Heiberger K.M. Glogauer M. el-Hashemite N. Onda H. Hum. Mol. Genet. 2002; 11: 525-534Crossref PubMed Scopus (538) Google Scholar, 11Goncharova E.A. Goncharov D.A. Eszterhas A. Hunter D.S. Glassberg M.K. Yeung R.S. Walker C.L. Noonan D. Kwiatkowski D.J. Chou M.M. Panettieri Jr., R.A. Krymskaya V.P. J. Biol. Chem. 2002; 277: 30958-30967Abstract Full Text Full Text PDF PubMed Scopus (373) Google Scholar). This inhibition occurs via the GAP (GTPase-activating protein) domain of TSC2. The target of the GAP activity of TSC2 is the small G protein Rheb, a potent positive upstream regulator of mTOR (12Zhang Y. Gao X. Saucedo L.J. Ru B. Edgar B.A. Pan D. Nat. Cell Biol. 2003; 5: 578-581Crossref PubMed Scopus (716) Google Scholar, 13Stocker H. Radimerski T. Schindelholz B. Wittwer F. Belawat P. Daram P. Breuer S. Thomas G. Hafen E. Nat. Cell Biol. 2003; 5: 559-565Crossref PubMed Scopus (434) Google Scholar, 14Saucedo L.J. Gao X. Chiarelli D.A. Li L. Pan D. Edgar B.A. Nat. Cell Biol. 2003; 5: 566-571Crossref PubMed Scopus (535) Google Scholar). Several studies have found that TSC2 stimulates GTP hydrolysis and inactivation of Rheb both in vivo and in vitro (15Li Y. Corradetti M.N. Inoki K. Guan K.L. Trends Biochem. Sci. 2004; 29: 32-38Abstract Full Text Full Text PDF PubMed Scopus (335) Google Scholar, 16Manning B.D. Cantley L.C. Trends Biochem. Sci. 2003; 28: 573-576Abstract Full Text Full Text PDF PubMed Scopus (395) Google Scholar). Many of the signals known to impinge upon mTOR act through TSC2. For example, we have recently found that the AMP-activated protein kinase (AMPK) directly phosphorylates and activates TSC2, thereby inhibiting translation through mTOR (17Inoki K. Zhu T. Guan K.L. Cell. 2003; 115: 577-590Abstract Full Text Full Text PDF PubMed Scopus (3013) Google Scholar). AMPK is a serine/threonine kinase that is activated in response to low energy conditions. Under such conditions of ATP depletion, AMPK phosphorylates numerous substrates to enhance catabolism and suppress anabolism (18Hardie D.G. Hawley S.A. BioEssays. 2001; 23: 1112-1119Crossref PubMed Scopus (676) Google Scholar). AMPK-mediated activation of TSC2 suppresses mTOR, as assayed by the inhibition of the phosphorylation of the mTOR targets S6K and 4EBP1, reduction in cellular protein synthesis, and a decrease in the overall size of cells (17Inoki K. Zhu T. Guan K.L. Cell. 2003; 115: 577-590Abstract Full Text Full Text PDF PubMed Scopus (3013) Google Scholar). Therefore, the TSC2-mTOR pathway plays a critical role in the coordination between cellular energy levels and cell growth. In addition to low energy levels, it has been proposed that activation of AMPK is also responsible for coupling other stressors, such as osmotic stress, heat shock, or hypoxia to signaling through mTOR (19Hardie D.G. J. Cell Sci. 2004; 117: 5479-5487Crossref PubMed Scopus (962) Google Scholar). AKT is a pro-survival kinase that is activated by insulin stimulation and positively regulates mTOR signaling by phosphorylating and inactivating TSC2 (9Inoki K. Li Y. Zhu T. Wu J. Guan K.L. Nat. Cell Biol. 2002; 4: 648-657Crossref PubMed Scopus (2406) Google Scholar, 20Manning B.D. Tee A.R. Logsdon M.N. Blenis J. Cantley L.C. Mol. Cell. 2002; 10: 151-162Abstract Full Text Full Text PDF PubMed Scopus (1278) Google Scholar, 21Potter C.J. Pedraza L.G. Xu T. Nat. Cell Biol. 2002; 4: 658-665Crossref PubMed Scopus (780) Google Scholar). AKT may also stimulate mTOR independently of TSC2 phosphorylation (22Dong J. Pan D. Genes Dev. 2004; 18: 2479-2484Crossref PubMed Scopus (93) Google Scholar). Recently, Reiling and Hafen (23Reiling J.H. Hafen E. Genes Dev. 2004; 18: 2879-2892Crossref PubMed Scopus (249) Google Scholar) performed a genetic screen in Drosophila for genes that, when overexpressed, suppressed an mTOR hyperactivation phenotype downstream of AKT. Two hypoxia-induced proteins, termed Scylla and Charybdis, were identified from the genetic screen as negative regulators of the Drosophila TOR pathway. In this paper we investigate the mammalian orthologs of Scylla and Charybdis, RTP801 (also known as Redd1 and dig2) and RTP801L (also known as Redd2). RTP801 and RTP801L share ∼50% sequence identity to each other but show little homology to other known proteins. We show that both RTP801 and RTP801L function as potent negative regulators of the mammalian target of rapamycin. Furthermore, we show that these proteins function upstream of TSC2 and Rheb. Since RTP801 and RTP801L are up-regulated at the transcriptional level in response to a variety of stresses, including DNA damage, hypoxia, and glucocorticoid treatment (23Reiling J.H. Hafen E. Genes Dev. 2004; 18: 2879-2892Crossref PubMed Scopus (249) Google Scholar, 24Ellisen L.W. Ramsayer K.D. Johannessen C.M. Yang A. Beppu H. Minda K. Oliner J.D. McKeon F. Haber D.A. Mol. Cell. 2002; 10: 995-1005Abstract Full Text Full Text PDF PubMed Scopus (392) Google Scholar, 25Lee M.J. Kim J.Y. Suk K. Park J.H. Mol. Cell. Biol. 2004; 24: 3918-3927Crossref PubMed Scopus (83) Google Scholar, 26Shoshani T. Faerman A. Mett I. Zelin E. Tenne T. Gorodin S. Moshel Y. Elbaz S. Budanov A. Chajut A. Kalinski H. Kamer I. Rozen A. Mor O. Keshet E. Leshkowitz D. Einat P. Skaliter R. Feinstein E. Mol. Cell. Biol. 2002; 22: 2283-2293Crossref PubMed Scopus (477) Google Scholar, 27Wang Z. Malone M.H. Thomenius M.J. Zhong F. Xu F. Distelhorst C.W. J. Biol. Chem. 2003; 278: 27053-27058Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar), we speculate RTP801 and RTP801L may play critical roles in coupling certain extra- and intracellular cues to the regulation of translation through mTOR. Antibodies, Plasmids, and Materials—Anti- phospho-GSK3β (S9) was obtained from Upstate (Charlottseville, VA). Anti-TSC2 antibodies were from Santa Cruz Biotechnololgy (Santa Cruz, CA). Anti-FLAG was from Sigma, and anti-HA and anti-Myc were obtained from Covance (Philadelphia, PA). Anti-Drosophila S6K was the generous gift of M. Stewart (28Stewart M.J. Berry C.O. Zilberman F. Thomas G. Kozma S.C. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 10791-10796Crossref PubMed Scopus (40) Google Scholar), and anti-RTP801 antiserum was the generous gift of L. Ellisen (24Ellisen L.W. Ramsayer K.D. Johannessen C.M. Yang A. Beppu H. Minda K. Oliner J.D. McKeon F. Haber D.A. Mol. Cell. 2002; 10: 995-1005Abstract Full Text Full Text PDF PubMed Scopus (392) Google Scholar). Anti-horseradish peroxidase-conjugated IgG secondary antibodies were obtained from Amersham Biosciences (Buckinghamshire, UK). All other antibodies were obtained from Cell Signaling. HA-tagged S6K (αII), FLAG-tagged 4EBP1, and GST-Akt were described previously (9Inoki K. Li Y. Zhu T. Wu J. Guan K.L. Nat. Cell Biol. 2002; 4: 648-657Crossref PubMed Scopus (2406) Google Scholar). Myc-tagged Rheb and Rheb-L64 were also described previously (29Inoki K. Li Y. Xu T. Guan K.L. Genes Dev. 2003; 17: 1829-1834Crossref PubMed Scopus (1424) Google Scholar). RTP801 and RTP801L constructs were generated by PCR subcloning from IMAGE consortium clones 4302878 and 3877854 into the pCDNA3–3xHA and pPGS-cite-neo-HA vectors, between BamHI and EcoRI cloning sites. All newly made constructs were verified by DNA sequencing. The AMPK inhibitor, commonly known as compound C, was obtained from Merck and was described previously (30Zhou G. Myers R. Li Y. Chen Y. Shen X. Fenyk-Melody J. Wu M. Ventre J. Doebber T. Fujii N. Musi N. Hirshman M.F. Goodyear L.J. Moller D.E. J. Clin. Invest. 2001; 108: 1167-1174Crossref PubMed Scopus (4432) Google Scholar). Intact cells were treated with a 40 μm concentration of the compound suspended in Me2SO for 3 h preceding lysis. Rapamycin was purchased from Cell Signaling and was suspended in methanol. Negative controls for all experiments with pharmacological reagents included vehicle. Cell Culture, Transfection, and Immunoprecipitation—Mammalian cell types were cultured and transfected as described previously (30Zhou G. Myers R. Li Y. Chen Y. Shen X. Fenyk-Melody J. Wu M. Ventre J. Doebber T. Fujii N. Musi N. Hirshman M.F. Goodyear L.J. Moller D.E. J. Clin. Invest. 2001; 108: 1167-1174Crossref PubMed Scopus (4432) Google Scholar). TSC2+/+ and TSC2–/– MEFs were obtained from D. Kwiatkowski. Cells were cultured for ∼48 h post-transfection unless otherwise noted, harvested in a mild lysis buffer, and subjected to SDS-PAGE and Western analysis as described previously (31Corradetti M.N. Inoki K. Bardeesy N. DePinho R.A. Guan K.L. Genes Dev. 2004; 18: 1533-1538Crossref PubMed Scopus (469) Google Scholar). All immunoblots represent the best example of at least two repeated experimental trials. Immunoprecipitations were performed as described previously (31Corradetti M.N. Inoki K. Bardeesy N. DePinho R.A. Guan K.L. Genes Dev. 2004; 18: 1533-1538Crossref PubMed Scopus (469) Google Scholar). Retroviral Infection—Retroviral infection was performed by transfecting 293 Phoenix retrovirus packaging cells with empty vector or pPGS-CITE-neo-HA-RTP801 and RTP801L as described previously (17Inoki K. Zhu T. Guan K.L. Cell. 2003; 115: 577-590Abstract Full Text Full Text PDF PubMed Scopus (3013) Google Scholar). RNA Interference (RNAi)—RTP801, RTP801L, and TSC2 short interfering RNAi oligonucleotides were purchased from Dharmacon (Denver, CO). Each siRNA is a pool of four siRNAs directed against RTP801 or RTP801L. Oligonucleotides were transfected into HEK293 cells, and lysates were made ∼48 h post-transfection. Double-stranded RNAi against Scylla and Charybdis was made and used to treat S2 cells according to the method of Worby et al. (32Worby C.A. Simonson-Leff N. Dixon J.E. Science's STKE. 2001; 2001: PL1PubMed Google Scholar). To determine whether RTP801 and RTP801L function to suppress signaling through the mammalian target of rapamycin, we determined the effect of overexpressed RTP801 and RTP801L on the key mTOR targets S6K and 4EBP1 in HEK293 cells. Our data show that both overexpressed RTP801 and RTP801L cause a dose-dependent inhibition of phosphorylation of co-transfected S6K (Fig. 1A). The data also imply that RTP801L may be a more potent inhibitor of S6K than RTP801, since lower expression levels of RTP801L are required to inhibit S6K than RTP801 (Fig. 1A and data not shown). The RTP801- and RTP801L-mediated inhibition of S6K was also observed in cells not indicating the effect is not to HEK293 cells. RTP801 and RTP801L also inhibit the phosphorylation of 4EBP1 (Fig. These results that of RTP801 and RTP801L potently inhibit signaling through mTOR. the of RTP801 and RTP801L in the regulation of S6K, we the effect of RTP801 and RTP801L in HEK293 cells. of HEK293 cells with short interfering RNA against RTP801 and RTP801L to an in S6K phosphorylation on and rapamycin treatment inhibited the effect of RTP801 or RTP801L RNAi (Fig. This was on both S6K (Fig. and on S6K (Fig. We also observed an in phosphorylation of the downstream target of S6K (Fig. RNA experiments with Scylla and Charybdis were performed in Drosophila S2 cells. of either Scylla or Charybdis phosphorylation of the Drosophila N. K. and with the these results support the role of RTP801 and RTP801L as potent negative regulators of signaling upstream of mTOR. To how RTP801 and RTP801L inhibit signaling through mTOR, we to determine how RTP801 and RTP801L function in the of known of the mTOR pathway. The serine/threonine AKT is a key positive regulator of mTOR that by phosphorylating and inactivating the tuberous sclerosis gene TSC2, a negative regulator of mTOR (9Inoki K. Li Y. Zhu T. Wu J. Guan K.L. Nat. Cell Biol. 2002; 4: 648-657Crossref PubMed Scopus (2406) Google Scholar, 20Manning B.D. Tee A.R. Logsdon M.N. Blenis J. Cantley L.C. Mol. Cell. 2002; 10: 151-162Abstract Full Text Full Text PDF PubMed Scopus (1278) Google Scholar, 21Potter C.J. Pedraza L.G. Xu T. Nat. Cell Biol. 2002; 4: 658-665Crossref PubMed Scopus (780) Google Scholar). Our results that of RTP801 and RTP801L in HEK293 cells has little effect on the phosphorylation and activation of a the activity of the AKT is to S6K (Fig. RNAi oligonucleotides directed against RTP801 and RTP801L have little effect on the phosphorylation of or a downstream target of (Fig. RTP801 and RTP801L inhibited S6K phosphorylation (Fig. The effect of RTP801L expression on S6K phosphorylation was by of RNAi and RTP801L siRNA also the expression of co-transfected (Fig. these results that RTP801 and RTP801L act downstream of AKT in mammalian cells. We also the of RTP801 and RTP801L to AMPK, known of the mTOR pathway (17Inoki K. Zhu T. Guan K.L. Cell. 2003; 115: 577-590Abstract Full Text Full Text PDF PubMed Scopus (3013) Google Scholar). To this we used a pharmacological inhibitor of AMPK known as that AMPK and not upstream kinase (30Zhou G. Myers R. Li Y. Chen Y. Shen X. Fenyk-Melody J. Wu M. Ventre J. Doebber T. Fujii N. Musi N. Hirshman M.F. Goodyear L.J. Moller D.E. J. Clin. Invest. 2001; 108: 1167-1174Crossref PubMed Scopus (4432) Google Scholar, M.N. Inoki K. Bardeesy N. DePinho R.A. Guan K.L. Genes Dev. 2004; 18: 1533-1538Crossref PubMed Scopus (469) Google Scholar). RTP801 and RTP801L were to inhibit S6K phosphorylation in the of C, not as as in the absence of the compound (Fig. In siRNA directed against RTP801 and RTP801L not have a effect on AMPK phosphorylation (Fig. these data imply that RTP801 and RTP801L not act upstream of However, from these data we whether RTP801 and RTP801L act downstream of AMPK or to To determine the between RTP801, RTP801L, and TSC2, we the TSC2 protein with siRNA The results that RTP801 and RTP801L were to inhibit S6K in the of TSC2 RNAi oligonucleotides (Fig. To the between RTP801, RTP801L, and TSC2, we RTP801 and RTP801L via infection in TSC2+/+ and TSC2–/– cells. Our results show that of RTP801 and RTP801L cause a reduction in S6K phosphorylation in TSC2+/+ cells but not TSC2–/– cells (Fig. with these RTP801 and RTP801L are to suppress S6K in the of overexpressed Rheb, the downstream target of TSC2 (Fig. The of RTP801 and RTP801L to suppress S6K was observed in the of either Rheb or Rheb a more of Rheb. Therefore, RTP801 and RTP801L function upstream of TSC2 and Rheb to inhibit mTOR RTP801 and RTP801L function to inhibit signaling through the mammalian target of rapamycin, it is not that are regulated by all the since the of are more is known regulation of RTP801 than RTP801L, to the of RTP801L to RTP801 (24Ellisen L.W. Ramsayer K.D. Johannessen C.M. Yang A. Beppu H. Minda K. Oliner J.D. McKeon F. Haber D.A. Mol. Cell. 2002; 10: 995-1005Abstract Full Text Full Text PDF PubMed Scopus (392) Google Scholar). RTP801 has been shown to be up-regulated by hypoxia via the hypoxia factor T. Faerman A. Mett I. Zelin E. Tenne T. Gorodin S. Moshel Y. Elbaz S. Budanov A. Chajut A. Kalinski H. Kamer I. Rozen A. Mor O. Keshet E. Leshkowitz D. Einat P. Skaliter R. Feinstein E. Mol. Cell. Biol. 2002; 22: 2283-2293Crossref PubMed Scopus (477) Google Scholar). has also been shown that RTP801 is up-regulated by treatment with the glucocorticoid Z. Malone M.H. Thomenius M.J. Zhong F. Xu F. Distelhorst C.W. J. Biol. Chem. 2003; 278: 27053-27058Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar). such as have been shown to cause a inhibition of S6K in cells that the glucocorticoid A. J. Biol. Chem. 2002; 277: Full Text Full Text PDF PubMed Scopus Google Scholar, M. Blenis J. Mol. 1996; 10: Google Scholar), that the of the rapamycin and glucocorticoid may at least share a mechanism of we speculate that since RTP801 (also gene dig2) has been shown to be and up-regulated by Z. Malone M.H. Thomenius M.J. Zhong F. Xu F. Distelhorst C.W. J. Biol. Chem. 2003; 278: 27053-27058Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar), it is possible that inhibition of S6K through a mechanism that In it has been that in response to DNA damage, cellular of genes is through a mechanism that the factor work has been performed on the regulation of translation in response to DNA damage, but it has been shown that several DNA cause inhibition of signaling through mTOR A.R. Oncogene. PubMed Scopus Google Scholar, DNA 2004; PubMed Scopus Google Scholar). Since it has also been shown that a variety of DNA including and the DNA cause a and in the of RTP801 (24Ellisen L.W. Ramsayer K.D. Johannessen C.M. Yang A. Beppu H. Minda K. Oliner J.D. McKeon F. Haber D.A. Mol. Cell. 2002; 10: 995-1005Abstract Full Text Full Text PDF PubMed Scopus (392) Google Scholar, 27Wang Z. Malone M.H. Thomenius M.J. Zhong F. Xu F. Distelhorst C.W. J. Biol. Chem. 2003; 278: 27053-27058Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar), studies be at whether RTP801 RTP801L play role in coupling the of the cell to DNA damage and the reduction in translation through mTOR. be critical in the to determine how the of RTP801 and RTP801L to inhibition of signaling through mTOR. RTP801 and RTP801L little homology to known protein whether these proteins whether as proteins, or whether have mechanism of also to be whether RTP801 and RTP801L TSC2 GAP The that RNAi against either RTP801 or RTP801L S6K phosphorylation more in cells cultured in than not that these two gene may play a more prominent role in mTOR regulation growth conditions as to conditions. the and experiments described in this that RTP801 and RTP801L play a role to inhibit the mTOR pathway (Fig. be that, the of this were also made by et al. J. K. Manning B.D. Reiling J.H. Hafen E. Ellisen L.W. Jr., Genes Dev. 2004; 18: PubMed Scopus Google Scholar). studies that RTP801 and RTP801L act upstream of TSC2, Rheb, and mTOR and downstream of AKT. These results are with genetic studies by Reiling and Hafen (23Reiling J.H. Hafen E. Genes Dev. 2004; 18: 2879-2892Crossref PubMed Scopus (249) Google Scholar) that Scylla and Charybdis, the Drosophila of RTP801 and RTP801L, the TOR pathway in RTP801 and RTP801L be as upstream of signals by stressors to mTOR, but it is that the molecular mechanism of RTP801 and RTP801L in mTOR inhibition We the of the Guan for critical of this and We also Ellisen for the RTP801
25
Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou, Robert P. Myers, Ying Li et al. · Journal of Clinical Investigation · 2001 · 5.4K citations
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Ken Inoki, Tianqing Zhu, Kun‐Liang Guan · Cell · 2003 · 3.9K citations · Full text
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Ken Inoki, Yong Li, Tianquan Zhu et al. · Nature Cell Biology · 2002 · 3.1K citations
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Ken Inoki, Yong Li, Tian Xu et al. · Genes & Development · 2003 · 1.9K citations · Full text
Brendan D. Manning, Andrew R. Tee, M. Nicole Logsdon et al. · Molecular Cell · 2002 · 1.6K citations · Full text